Cargando…

Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment

This paper reviews current treatments for renal cell carcinoma/cancer (RCC) with the multikinase inhibitors (MKIs) sorafenib, sunitinib, lenvatinib and axitinib. Furthermore, it compares these drugs regarding progression-free survival, overall survival and adverse effects (AE), with a focus on hyper...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bæk Møller, Nanna, Budolfsen, Cecilie, Grimm, Daniela, Krüger, Marcus, Infanger, Manfred, Wehland, Markus, E. Magnusson, Nils
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801695/ https://www.ncbi.nlm.nih.gov/pubmed/31547602 http://dx.doi.org/10.3390/ijms20194712

Ejemplares similares

Multikinase Inhibitor Treatment in Thyroid Cancer
por: Ancker, Ole Vincent, et al.
Publicado: (2019)

Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma
por: Bendtsen, Mathias Alrø Fichtner, et al.
Publicado: (2017)

Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma
por: Randrup Hansen, Caroline, et al.
Publicado: (2017)

The Vasoactive Mas Receptor in Essential Hypertension
por: Povlsen, Amalie L., et al.
Publicado: (2020)

SARS‐CoV‐2 and hypertension
por: Ravichandran, Briyanth, et al.
Publicado: (2021)

Biomarkers for Anti-Angiogenic Therapy in Cancer
por: Wehland, Markus, et al.
Publicado: (2013)

Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer—Focus on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension
por: Kaae, Anne Christine, et al.
Publicado: (2021)

Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
por: Stjepanovic, Neda, et al.
Publicado: (2014)

Use of multikinase inhibitors/lenvatinib in singular thyroid cancer scenarios
por: Zafón, Carles, et al.
Publicado: (2022)

The Effects of Oral l-Arginine and l-Citrulline Supplementation on Blood Pressure
por: Khalaf, David, et al.
Publicado: (2019)

Potential Beneficial Effects of Vitamin D in Coronary Artery Disease
por: Legarth, Christian, et al.
Publicado: (2019)

Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study
por: Cai, Wen, et al.
Publicado: (2019)

The Effect of Continuous Positive Airway Pressure Therapy on Obstructive Sleep Apnea-Related Hypertension
por: Baran, Ronni, et al.
Publicado: (2021)

Bioactive Candy: Effects of Licorice on the Cardiovascular System
por: Deutch, Mikkel R., et al.
Publicado: (2019)

Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension
por: Milling, Rikke Vilsbøll, et al.
Publicado: (2018)

The multikinase inhibitor axitinib in the treatment of advanced hepatocellular carcinoma: the current clinical applications and the molecular mechanisms
por: Jiang, Hao, et al.
Publicado: (2023)

The Adverse Effect of Hypertension in the Treatment of Thyroid Cancer with Multi-Kinase Inhibitors
por: Ancker, Ole Vincent, et al.
Publicado: (2017)

Endothelin Receptor Antagonists: Status Quo and Future Perspectives for Targeted Therapy
por: Enevoldsen, Frederik C., et al.
Publicado: (2020)

Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma
por: Zhang, Yue, et al.
Publicado: (2019)

Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
por: Herranz, Urbano Anido
Publicado: (2022)

Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells—A View towards Second Line Renal Cell Carcinoma Treatment
por: Juengel, Eva, et al.
Publicado: (2021)

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
por: Lai, You-Liang, et al.
Publicado: (2022)

Sorafenib, a multikinase inhibitor, induces formation of stress granules in hepatocarcinoma cells
por: Adjibade, Pauline, et al.
Publicado: (2015)

Sorafenib and sunitinib: A dermatologist's perspective
por: Pragasam, Vijendran, et al.
Publicado: (2014)

In vitro evaluation of Axitinib and Sorafenib treatment in glioblastoma cell viability and morphology
por: Opriţa, Alexandru, et al.
Publicado: (2023)

Use of multikinase inhibitors/lenvatinib concomitant with locoregional therapies for the treatment of radioiodine‐refractory differentiated thyroid cancer
por: Berciano‐Guerrero, Miguel‐Ángel
Publicado: (2022)

SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer
por: Kim, Soo Young, et al.
Publicado: (2018)

The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing
por: Tesori, Valentina, et al.
Publicado: (2015)

Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect
por: Højer Wang, Linnea, et al.
Publicado: (2023)

Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
por: Ikeda, Atsuyuki, et al.
Publicado: (2021)

Use of multikinase inhibitors/lenvatinib in patients with high cardiovascular risk/vasculopathy and radioiodine refractory‐differentiated thyroid cancer
por: Jimenez‐Fonseca, Paula
Publicado: (2022)

Use of multikinase inhibitors/lenvatinib in patients with synchronous/metachronous cancers coinciding with radioactive‐resistant differentiated thyroid cancer
por: Sambo, Marcel
Publicado: (2022)

Simulated Microgravity Influences VEGF, MAPK, and PAM Signaling in Prostate Cancer Cells
por: Hybel, Trine Engelbrecht, et al.
Publicado: (2020)

The Impact of Vitamin D in the Treatment of Essential Hypertension
por: Legarth, Christian, et al.
Publicado: (2018)

Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats
por: Cui, Yanjun, et al.
Publicado: (2022)

Semantic Analysis of Posttranslational Modification of Proteins Accumulated in Thyroid Cancer Cells Exposed to Simulated Microgravity
por: Bauer, Johann, et al.
Publicado: (2018)

Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis
por: Wen, Tingyu, et al.
Publicado: (2017)

Mechanisms of three-dimensional growth of thyroid cells during long-term simulated microgravity
por: Kopp, Sascha, et al.
Publicado: (2015)

Use of multikinase inhibitors/lenvatinib concomitant with antiresorptive therapy for bone metastases from radioiodine‐resistant differentiated thyroid cancer
por: Navarro‐Gonzalez, Elena
Publicado: (2022)

Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer
por: Liu, Dai, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ub67ibarfv2qqh45cmjcemc1st